Page last updated: 2024-10-22

alendronate and Hereditary Autoinflammation Diseases

alendronate has been researched along with Hereditary Autoinflammation Diseases in 1 studies

alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.

Research Excerpts

ExcerptRelevanceReference
" We report on a 35-year-old female who was diagnosed with TRAPS, after finding the V95M mutation on the TNFRSF1A gene; who was treated in order with etanercept, anakinra, and canakinumab (150 mg/every 8 weeks by subcutaneous injection, then increased to 150 mg every 4 weeks); and who started therapy with oral alendronate (70 mg/weekly) to control her osteoporosis."3.81Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate. ( Cantarini, L; Frediani, B; Iannone, F; Lopalco, G; Rigante, D; Vitale, A, 2015)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lopalco, G1
Rigante, D1
Vitale, A1
Frediani, B1
Iannone, F1
Cantarini, L1

Other Studies

1 other study available for alendronate and Hereditary Autoinflammation Diseases

ArticleYear
Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate.
    Clinical rheumatology, 2015, Volume: 34, Issue:4

    Topics: Adult; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Drug Therapy, Combina

2015